地塞米松缓释剂在白内障超声乳化摘除人工晶状体植入术中的临床应用  

Clinical observation of anterior chamber implantation of dexamethasone sustained release microcapsules during phacoemulsification and intraocular lens operation

作　　者：高潮[1] 王志立[1] 戴晓东[1] 

机构地区：[1]温州医学院附属第三医院眼科,325200

出　　处：《临床眼科杂志》2005年第1期35-37,共3页Journal of Clinical Ophthalmology

基　　金：浙江省瑞安市科技局基金资助

摘　　要：目的　观察地塞米松缓释剂 (思诺迪清 )前房植入对白内障超声乳化摘除人工晶状体植入术后后囊混浊的预防效果。方法　将 2 0 0 1年 6月～ 2 0 0 2年 1月在我院手术的年龄相关性白内障患者随机分为 A、B两组。A组 (右眼 ,5 0例 )术中前房植入地塞米松缓释剂一粒 ,B组 (左眼 ,4 6例 )作为对照组 ,术中前房未植入地塞米松缓释剂。随访 2年 ,观察两组术后前房炎症及后发障的发生率。结果　术后前房炎症反应有显著性差异 (P <0 .0 5 )。后囊混浊的发生情况 :轻度者有显著性差异 (P <0 .0 5 ) ,重度者无显著性差异 (P >0 .0 5 )。结论　前房内植入地塞米松缓释剂可以减轻炎症 ,但不能有效地预防后发障的发生。Objective To evaluate the effect of dexamethasone sustained release microcapsules implanted in anterior chamber during phacoemulsification and intraocular lens implantation operation. Methods Age-related cataract operation cases from 2001.6 to 2002.1 were divided into groups A (right eyes, 50 cases ) and B (left eyes, 46 cases ). Group A were implanted dexamethasone sustained release microcapsules in the anterior chamber and group B without that during phacoemulsification and intraocular lens implantation operation. Results There was significance between two groups in anterior chamber inflammation and posterior capsule opacificationⅠ,but was not in posterior capsule opacification Ⅱ and more (P>0.05 ).Conclusion Dexamethasone sustained release microcapsules could abate anterior inflammation, whereas could not prevent posterior capsule opacification effectively.

关 键 词：地塞米松缓释剂 白内障 超声乳化摘除 人工晶状体植入术 临床应用 

分 类 号：R779.66[医药卫生—眼科]